Publications by authors named "Marie Alt"

Claim this Profile
F
Fabrication and Characterization of PDMS Waveguides for Flexible Optrodes.
Linda Rudmann, Daniel Scholz, Marie T Alt, Alexander Dieter, Eva Fiedler

Adv Healthc Mater· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.
Marie Alt, Carlos Stecca, Yian Lin, Gbenga Kazeem, Erik T Goluboff

BMC Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC).
Carlos E Stecca, Marie Alt, Di Maria Jiang, Glaucia Michelis, Nazanin Fallah-Rad

Semin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Grégoire Marret, Nicolas Isambert, Keyvan Rezai, Jocelyn Gal, Esma Saada-Bouzid, Marie Alt

Invest New Drugs· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature.
Carlos E Stecca, Marie Alt, Di Maria Jiang, Peter Chung, Juanita M Crook

Oncol Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enfortumab Vedotin in urothelial cancer.
Marie Alt, Carlos Stecca, Swanee Tobin, Di Maria Jiang, Srikala S Sridhar

Ther Adv Urol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial.
Clémence Basse, Claire Morel, Céline Callens, Gaëlle Pierron, Vincent Servois, Marie Alt

JCO Precis Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implantable Glass Waveguides and Coating Materials for Chronic Optical Medical Applications.
Marie T Alt, Annette Mittnacht, Thomas Stieglitz

Annu Int Conf IEEE Eng Med Biol Soc· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.
Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, Christophe Massard, Elena Garralda, Marie Alt

Clin Cancer Res· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.
Sophie Outh-Gauer, Marie Alt, Christophe Le Tourneau, Jérémy Augustin, Chloé Broudin

Cancer Treat Rev· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.
Clémence Basse, Claire Morel, Marie Alt, Marie Paule Sablin, Coralie Franck

ESMO Open· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab Associated with Chemotherapy for Initially Non-resectable Liver Metastases from Colorectal Cancer: a Case-Control Study.
Marie Alt, Stéphanie Truant, Thibaut Renaud-Vantroys, Cédric Séquier, Alain Duhamel

Anticancer Res· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.
Christophe Le Tourneau, Maud Kamal, Apostolia-Maria Tsimberidou, Philippe Bedard, Gaëlle Pierron, Marie Alt

J Natl Cancer Inst· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials.
Loic Verlingue, Marie Alt, Maud Kamal, Marie-Paule Sablin, Mustapha Zoubir

Per Med· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The spectrum of clinical trials aiming at personalizing medicine.
Christophe Le Tourneau, Maud Kamal, Marie Alt, Loic Verlingue, Vincent Servois

Chin Clin Oncol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
Marie Vanhuyse, Nicolas Penel, Armelle Caty, Ingrid Fumagalli, Marie Alt

Bull Cancer· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hybrid surface design for robust superhydrophobicity.
Susmita Dash, Marie T Alt, Suresh V Garimella

Langmuir· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis